Similarly, in children with intermediate-risk rhabdomyosarcoma randomized to receive standard of care chemotherapy with or without the mTOR inhibitor temsirolimus, no difference in event-free survival was observed in the ARST1431 study [186]. The gene discussed is MTOR; the disease is rhabdomyosarcoma.